



151
JP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Stanton et al.
Appl. No. : 09/665,728
Filed : September 20, 2000
For : SECRETED FACTORS
Examiner : Eileen B. O'Hara, Ph.D.

) Group Art Unit 1646

) I hereby certify that this correspondence
) and all marked attachments are being
) deposited with the United States Postal
) Service as first-class mail in an envelope
) addressed to: United States Patent and
) Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

) December 23, 2002

) (Date)

) 
) James J. Mullen III, Ph.D.,
) Reg. No. 44,957

O/K to enter
EPA
1/29/03

RESPONSE AFTER FINAL

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202
ATTENTION BOX: AF

RECEIVED
JAN 02 2003
TECH CENTER 1600/2900

Dear Sir:

In response to the final Office Action mailed October 22, 2002, please consider the following remarks.

IN THE CLAIMS

Please amend Claims 1-4, 30, and 32 as follows:

1. (Thrice amended) An isolated nucleic acid molecule comprising a poly- or oligonucleotide selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide having at least 90% sequence identity with SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model;

(b) a polynucleotide encoding a polypeptide having at least 90% sequence identity with amino acids 22 to 122 of SEQ ID NO:1, wherein the complement of said

P1